Original Article
Naltrexone in the Treatment of Alcohol Dependence
N Engl J Med 2001; 345:1734-1739December 13, 2001
- Abstract
Background
Although naltrexone, an opiate-receptor antagonist, has been approved by the Food and Drug Administration for the treatment of alcohol dependence, its efficacy is uncertain.
Methods
We conducted a multicenter, double-blind, placebo-controlled evaluation of naltrexone as an adjunct to standardized psychosocial treatment. We randomly assigned 627 veterans (almost all men) with chronic, severe alcohol dependence to 12 months of naltrexone (50 mg once daily), 3 months of naltrexone followed by 9 months of placebo, or 12 months of placebo. All patients were offered individual counseling and programs to improve their compliance with study medication and were encouraged to attend Alcoholics Anonymous meetings.
Results
There were 209 patients in each group; all had been sober for at least five days before randomization. At 13 weeks, we found no significant difference in the number of days to relapse between patients in the two naltrexone groups (mean, 72.3 days) and the placebo group (mean, 62.4 days; 95 percent confidence interval for the difference between groups, –3.0 to 22.8). At 52 weeks, there were no significant differences among the three groups in the percentage of days on which drinking occurred and the number of drinks per drinking day.
Conclusions
Our findings do not support the use of naltrexone for the treatment of men with chronic, severe alcohol dependence.
Media in This Article
Table 1
Base-Line Characteristics of the 627 Patients.Table 2
Adverse Events Reported More Commonly in the Naltrexone Group Than in the Placebo Group.Article Activity
- Article
Alcoholism is a devastating medical illness with a profound public health impact.1 In 1995, because of its extensive record for safety when administered for other indications, the Food and Drug Administration (FDA) approved naltrexone, an opioid-receptor antagonist, for the treatment of ethanol dependence, in part on the basis of two well-designed single-site studies.2-4 The initial studies suggested that naltrexone substantially increased sobriety and reduced ethanol consumption when combined with psychosocial treatment.
Naltrexone was incorporated into the treatment of alcoholism on the premise that stimulation of the μ opioid receptor contributed to the rewarding effects of alcohol.5-7 Data from clinical trials suggested that naltrexone reduced the rewarding effects of alcohol and contributed to reduced alcohol craving and lower alcohol consumption.8,9 Subsequent studies suggested that naltrexone was less effective for treating alcohol dependence and had more adverse effects than was initially suggested.10-15 We conducted a multicenter, double-blind, placebo-controlled evaluation of the efficacy of naltrexone when administered for 3 or 12 months as an adjunct to standardized psychosocial treatment.
Methods
Protocol
The Human Rights Committees of the Department of Veterans Affairs Cooperative Studies Program and the 15 participating Veterans Affairs medical centers approved this study. All patients provided written informed consent. An independent data and safety monitoring board monitored patient safety.
The three treatment groups were as follows: patients in the long-term naltrexone group were treated with naltrexone (ReVia, Dupont Pharma) for 12 months; patients in the short-term naltrexone group were treated with naltrexone for 3 months and then received placebo for 9 months; and patients in the placebo group received placebo for 12 months. During a six-month post-treatment follow-up, we assessed the durability of improvement after the period of randomized treatment. Patients were asked to continue through the 18-month follow-up even if they discontinued the study medication or counseling.
Patients were enrolled over a two-year period. Double-blind treatment was initiated within a day of randomization. Patients receiving naltrexone started with 25 mg once daily for 2 days, followed by 50 mg once daily for 3 or 12 months. The short-term naltrexone group was switched in a double-blind fashion to matching placebo when naltrexone was discontinued at the 13-week visit. Patients assigned to placebo received one placebo tablet daily for 12 months. Medication for all groups was discontinued after 12 months.
Enhancement of Compliance
Medication was provided in bottles with caps (MEMS, Aprex, Union City, Calif.) that recorded the date and time of each opening and showed the number of hours that had elapsed since the previous opening. All patients participated in a feedback program designed to enhance compliance with the once-daily medication regimen for 12 months.16 The Medication Usage Skills for Effectiveness monthly feedback system has been demonstrated to enhance compliance among patients with psychiatric disorders by teaching daily cues (e.g., linking doses to a specific time, meal, or daily activity) and reviewing dosing calendars on a computer screen (with data downloaded from the patients' MEMS caps).16,17 Plasma 6-beta-naltrexol was measured in some patients at 13 and 24 weeks.
Counseling
Patients received individual 12-step facilitation counseling18 for 13 months and were encouraged to attend Alcoholics Anonymous meetings. Counseling was aimed at reinforcing abstinence, providing basic relapse-prevention information, promoting acceptance of drug therapy, and reducing attrition. Visits were once weekly for 16 weeks, every 2 weeks during weeks 17 to 36, and once monthly during weeks 37 to 56.
Screening and Eligibility Criteria
We screened veterans 18 years of age or older who had a recent history of drinking to intoxication (heavy drinking two times in at least 1 week in the 30 days before screening) and who had been given a diagnosis of alcohol dependence according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV).19 All patients were outpatients who had been sober for five days before randomization. Specific exclusion criteria included previous use of naltrexone, liver disease, a psychiatric diagnosis other than alcoholism requiring current psychotropic medication, homelessness, other substance abuse or dependence (excluding nicotine or occasional marijuana use), any past illicit opiate use, and marijuana dependence. Patients who had pending legal charges with the potential for incarceration or who received a disability pension related to alcoholism were excluded, to avoid any secondary motive to sustain disability status or legally imposed treatment requirements.
Base-line and monthly assessments included a review of drinking,20 medication use, and counseling progress. Compensation ($20) was provided for the time required to complete monthly ratings, including drinking calendars, whether the patient was taking a study medication, attended counseling sessions or Alcoholics Anonymous meetings, or had discontinued participation. Longer interviews at 6, 12, and 18 months were compensated at $50 per session.
Outcomes
Three variables were defined that would allow us to answer the primary questions of the study (at 3 and 12 months): time to relapse during the first 3 months (number of days from randomization until relapse, with relapse defined as the first day of heavy drinking [six or more drinks for men and four or more for women]); the percentage of drinking days over a 12-month period (the number of drinking days reported during that period divided by the number of days for which data were available); and number of drinks per drinking day over a 12-month period (the total number of drinks reported during the period divided by the number of days on which consumption of one or more drinks was reported).
Our objectives were to determine whether the short-term (3-month) use of naltrexone, as compared with placebo, decreased drinking (measured by the time to relapse) in alcohol-dependent patients and whether the long-term (12-month) use of naltrexone, as compared with placebo and short-term naltrexone, decreased drinking (measured by the percentage of drinking days and the number of drinks per drinking day).
Statistical Analysis
Data were held and analyzed by the Veterans Affairs Cooperative Studies Program. A two-sided level of significance of 0.0167 for each comparison among groups was needed to produce an overall P value of 0.05 after Bonferroni correction. The sample size of 200 yielded sufficient power for the comparison of the three-month curves for time to the first episode of heavy drinking.
The primary analysis was based on the intention to treat. Secondary analyses were planned on the basis of actual treatment or to include only patients who complied with the treatment regimen. The Kaplan–Meier product-limit estimator was used to estimate the time to the three-month outcomes.21 Differences in the proportion of drinking days and numbers of drinks per drinking day were analyzed by the chi-square test and t-test. Analyses of drinking days included only days for which data were available and on which the patient was able to drink (e.g., not incarcerated or hospitalized). Secondary analyses were performed by analysis of covariance and an accelerated failure-time model with the SAS procedure Lifereg.22 Compliance with medication was defined by the percentage of days on which the medication bottle was opened during the period; the covariates for counseling and Alcoholics Anonymous were the numbers of sessions attended during the period.
Results
The study was conducted from April 1997 to October 2000. We screened 3372 alcohol-dependent veterans to assign 627 patients to three groups of 209 patients each (with 30 to 50 patients per site). Base-line characteristics of the patients are shown in Table 1Table 1
Base-Line Characteristics of the 627 Patients., and adverse events during treatment in Table 2Table 2Adverse Events Reported More Commonly in the Naltrexone Group Than in the Placebo Group.. There were no significant differences among the groups in any base-line measures (except family history of alcoholism) or follow-up measures of compliance with the protocol (Table 3Table 3
Compliance with the Protocol.), including attendance at monthly follow-up visits, duration of compliance with the medication, percentage of days on which medication was taken, attendance at counseling sessions or Alcoholics Anonymous meetings, and adverse events. Overall, 73 percent of the patients completed the trial. The reasons for not completing the trial did not differ significantly among treatment groups: 95 patients were lost to follow-up, 21 withdrew, 14 moved or were unable to return, 12 died, and 28 discontinued participation for other reasons.MEMS monitors showed that 89 percent of the patients took at least some medication for 52 weeks. Plasma 6-beta-naltrexol levels in blood samples obtained from 189 patients at week 13 and 69 patients at week 24 were consistent with MEMS data; they showed that 84 percent of the patients were taking the medication. Complete drinking data were collected from 78 percent of the patients for the first 13 weeks and 52 percent of the patients for 52 weeks. Full or partial 52-week data on drinking were available for 93 percent of the patients.
In the first 13 weeks, we obtained data from 378 patients who received naltrexone and 187 patients who received placebo. We found no significant differences in the primary end point of time to relapse. The median time to relapse overall was 135 days. There were also no significant differences between the naltrexone groups and the placebo group in terms of the relapse rate, percentage of drinking days, or number of drinks per drinking day (Table 4Table 4
Outcomes of Treatment.). At 52 weeks, there were no significant differences among the three groups in the percentage of drinking days or the number of drinks per drinking day (Table 4).Patients who were more compliant with medication and those who attended more counseling or Alcoholics Anonymous sessions had better outcomes, whether they took naltrexone or placebo (Table 5Table 5
Secondary Analyses of Primary End Points.). Analyses of covariance, with one covariate taken at a time, showed that compliance with medication, counseling, and attendance at Alcoholics Anonymous meetings had strong effects on the number of days to relapse that were independent of treatment assignment. Analyses of covariance for the percentage of drinking days, taking one covariate at a time, showed that compliance with medication, counseling, and attendance at Alcoholics Anonymous also had strong effects that were independent of treatment assignment. None of the covariates alone had a significant effect on the number of drinks per drinking day (Table 5). Analyses of the multiple-covariate models found that attendance at counseling sessions and Alcoholics Anonymous meetings had the greatest effect on the percentage of drinking days and that compliance with medication had the greatest effect on the number of drinks per drinking day (Table 5).In post hoc analyses, we examined possible interactions of the primary outcomes with treatment site, disability, psychiatric diagnoses, family history, motivation,23 craving,24 dependence,25 and age at onset of drinking. No interactions were found (data not shown).
Discussion
In this large, multisite study, in which we used the same alcoholism outcome measures that were employed in earlier single-site studies, we did not detect an effect of naltrexone. Relative to placebo, naltrexone did not prevent or delay relapse to heavy drinking, reduce the number of drinking days, or decrease the amount of alcohol consumed during episodes of drinking. Major outcomes were not influenced by the duration of naltrexone administration, the degree of compliance with study medication, participation in counseling sessions, or attendance at Alcoholics Anonymous meetings. Our data do not support the treatment of alcohol dependence with naltrexone combined with a psychosocial treatment program in men with chronic, severe alcohol dependence.
Naltrexone is the second medication approved by the FDA for the treatment of alcoholism for which a finding of efficacy has not been replicated in a multicenter, placebo-controlled study. Disulfiram was the other.26 Previous small, single-site studies compared the short-term effects (over 12 weeks) of naltrexone and placebo.2,3,11,15 In a systematic review of previous studies, Garbutt et al. concluded that “naltrexone reduces the risk of relapse to heavy drinking and frequency of drinking compared with placebo but does not substantially enhance abstinence, i.e., avoidance of any alcohol consumption.”27 In contrast, we and others12,14 have found no significant differences in favor of short- or long-term naltrexone treatment. Our study was larger than other studies and had longer patient follow-up. Patients who interrupted their treatment were not dropped from the study and could return to treatment, as happens in clinical practice. Although the eligibility criteria stipulated a minimal drinking level, patients with high and low drinking rates at base line were enrolled equally in all treatment groups.
With respect to the level of training of counselors and the frequency of clinical contact, the counseling we provided was typical of treatment available within Veterans Affairs medical centers and was similar to that provided in previous studies. Consistently with previous studies, we found evidence that patients who were more compliant with prescribed medication, attended more counseling sessions, and participated in more Alcoholics Anonymous meetings had better treatment outcomes.28-30 However, these associations cannot be interpreted as causal, because abstinent patients might have been more likely to take medication, to attend counseling sessions, and to participate in Alcoholics Anonymous meetings. Our results were more consistent with those of two Veterans Affairs studies evaluating treatment for alcoholism, in which good compliance was associated with less drinking in the disulfiram, lithium, and placebo groups.29,30
Some limitations of our study should be noted. We studied a severely affected population typical of male Veterans Affairs patients: that is, older, heavier drinkers, with long duration of alcoholism. Inclusion of patients with mild alcohol dependence would increase variability in outcomes and require a larger sample to find differences. We cannot rule out the possibility that a different dose of naltrexone or the use of adjunctive medications along with naltrexone might have been effective in our patients. The results might not be generalizable to patients with less chronic and severe alcohol dependence, non–Veterans Affairs settings, or women.
In summary, in a large study, we found no evidence that naltrexone combined with psychosocial therapy was an effective treatment for alcohol dependence. Our data raise doubts about the current use of naltrexone for patients with chronic, severe alcohol dependence. Our findings do not rule out the possibility that naltrexone in combination with other medications or with other types of psychosocial interventions, or in other patient groups, may have a role in the treatment of alcoholism.
Supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development. Naltrexone and matching placebo were donated by Dupont Pharmaceuticals, which also analyzed blood naltrexone levels.
We are indebted to the members of the Data Monitoring Committee (K. Dickerson, Providence, R.I.; J. Fertig, Bethesda, Md.; M. Fisher, Madison, Wis.; H. Goldman, Baltimore; R. Meyer, Washington, D.C.; M. Shuckit, San Diego, Calif.) and the Planning Committee (R. Anton, Charleston, S.C.; S. O'Malley and B. Rounsaville, New Haven, Conn.; C. O'Brien and J. Volpicelli, Philadelphia).
Source Information
From the Department of Veterans Affairs Alcohol Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, Conn. (J.H.K., J.A.C., R.A.R.); the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. (J.H.K., J.A.C., R.A.R.); the Department of Veterans Affairs Cooperative Studies Program Coordinating Center, Perry Point, Md. (W.F.K., G.F.K.); and the Northeast Program Evaluation Center, Department of Veterans Affairs Connecticut Healthcare System, West Haven, Conn. (R.A.R.).
Address reprint requests to Dr. Krystal at the Alcohol Research Center (G7E), the Department of Veterans Affairs Connecticut Healthcare System, 950 Campbell Ave., West Haven, CT 06516-2770, or at john.krystal@yale.edu.
Appendix
In addition to the authors, the members of the Department of Veterans Affairs Cooperative Study 425 Group were as follows: K. Drexler, F. Mohammad, L. Siklosky, K. Walker, C. Arnold-Hunter, and R. Head, Atlanta; J. Hermos, H. Behr, B. Kinne, D. Savage, and J. Wickis, Boston; L. Rugle, O. Kausch, H. Zegarna, K. Conti, H. Adkins, G. Harris, and C. Cartier, Cleveland; B. Adinoff, L. Burney, J. Fields, B. Hudson, J. Corder, and A. Quintero, Dallas; J. Grabowski, R. Wancha, Y. Ruiz, S. Chermack, S. Fleming, K. Gamel, and B. Sullivan, Detroit; L. Madlock, R. Murray, J. Williams, R. Lewandowski, and T. Owens, Memphis, Tenn.; M. FeBornstein, J. Pena, B. Cotton-Brown, M. Cowie, A. Connelly, W. Hill, A. Holmes, and J. Fiery, New Orleans; P. Casadonte, S. Kushner, S. Johnson, J. Siegris, N. Lynch, E. Richardson, and A. Butcher, New York; S. Nixon, C. Shaw, R. Joswick, D. Bertoch, and H. Engebretson, Oklahoma City; L. Haynes-Tucker, L. Moffet, J. Weintraub, R. Lutz, S. Clinton, F. Pohlman, R. Royal, and S. Harris, Menlo Park, Calif.; I. Maany, J. DeStefano, M. Andem, C. Hackett, J. McNeely, S. Dyanick, D. Torpey, S. Poole, E. Moeller, and A. Scheamania, Philadelphia; G. Kaplan, H. MacAskill, P. Charnley, and C. Williams, Providence, R.I.; C. Stock, P. Stevenson, S. Plumb, M. Dean, and J. Hunter, Salt Lake City; P. Banys, I. Rhew, S. Staccone, J. Kelly, and S. Shives, San Francisco; A. Saxon, M. Willey-Allen, J. Williams, K. Lunna, V. Ruscigno, S. Brown, and K. Shaffer, Seattle; J. Collins, S. Kilby, T. Burke, L. Linzy, C. Dalzell, M. Rhoads, J. Kelly, N. Banks, J. Arflin, and D. Briones, Perry Point, Md.; and M. Miller and C. Messick, Albuquerque, N.M.
- References
References
1
Swift RM . Medications and alcohol craving. Alcohol Res Health 1999;23:207-213
Medline2
Volpicelli JR ,Alterman AI ,Hayashida M ,O'Brien CP . Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-880
Web of Science | Medline3
O'Malley SS ,Jaffe A ,Chang G ,Schottenfeld RS ,Meyer RE ,Rounsaville B . Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992;49:881-887
Web of Science | Medline4
O'Malley SS ,Croop RS ,Wroblewski JM ,Labriola DF ,Volpicelli JR . Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatr Ann 1995;25:681-688
Web of Science5
Gianoulakis C . Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol Suppl 1996;1:33-42
Medline6
Herz A . Endogenous opioid systems and alcohol addiction. Psychopharmacology 1997;129:99-111
CrossRef | Web of Science | Medline7
Swift RM ,Whelihan W ,Kuznetsov O ,Buongiorno G ,Hsuing H . Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994;151:1463-1467
Web of Science | Medline8
Volpicelli JR ,Watson NT ,King AC ,Sherman CE ,O'Brien CP . Effect of naltrexone on alcohol “high“ in alcoholics. Am J Psychiatry 1995;152:613-615
Web of Science | Medline9
O'Malley SS ,Jaffe AJ ,Rode S ,Rounsaville BJ . Experience of a “slip“ among alcoholics treated with naltrexone or placebo. Am J Psychiatry 1996;153:281-283
Web of Science | Medline10
Monti PM ,Rohsenow DJ ,Hutchison KE , et al. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 1999;23:1386-1394
Web of Science | Medline11
Volpicelli JR ,Rhines KC ,Rhines JS ,Volpicelli LA ,Alterman AI ,O'Brien CP . Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997;54:737-742
Web of Science | Medline12
Kranzler HR ,Modesto-Lowe V ,Van Kirk J . Naltrexone vs. nefazodone for treatment of alcohol dependence: a placebo-controlled trial. Neuropsychopharmacology 2000;22:493-503
CrossRef | Web of Science | Medline13
Croop RS ,Chick J . American and European clinical trial of naltrexone: international update: new findings on promising medications. Alcohol Clin Exp Res 1996;20:Suppl 8:216A-218A
CrossRef | Web of Science | Medline14
Chick J ,Anton R ,Checinski K , et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000;35:587-593
Web of Science | Medline15
Anton RF ,Moak DH ,Waid LR ,Latham PK ,Malcolm RJ ,Dias JK . Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999;156:1758-1764
Web of Science | Medline16
Cramer JA . Enhancing patient compliance in the elderly: role of packaging aids and monitoring. Drugs Aging 1998;12:7-15
CrossRef | Web of Science | Medline17
Cramer JA ,Rosenheck R . Enhancing medication compliance for people with serious mental illness. J Nerv Ment Dis 1999;187:53-55
CrossRef | Web of Science | Medline18
Project MATCH (Matching Alcoholism Treatment to Client Heterogeneity): rationale and methods for a multisite clinical trial matching patients to alcoholism treatment. Alcohol Clin Exp Res 1993;17:1130-1145
CrossRef | Web of Science | Medline19
Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
20
Sobell LC ,Sobell MB ,Leo GI ,Cancilla A . Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 1988;83:393-402
CrossRef | Medline21
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science22
Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
23
DiClemente CC ,Hughes SO . Stages of change profiles in outpatient alcoholism treatment. J Subst Abuse 1990;2:217-235
CrossRef | Medline24
Anton RF ,Moak DH ,Latham P . The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 1995;19:92-99
CrossRef | Web of Science | Medline25
Skinner HA ,Allen BA . Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 1982;91:199-209
CrossRef | Web of Science | Medline26
Fuller RK ,Branchey L ,Brightwell DR , et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986;256:1449-1455
CrossRef | Web of Science | Medline27
Garbutt JC ,West SL ,Carey TS ,Lohr KN ,Crews FT . Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999;281:1318-1325
CrossRef | Web of Science | Medline28
Fuller R ,Roth H ,Long S . Compliance with disulfiram treatment of alcoholism. J Chronic Dis 1983;36:161-170
CrossRef | Medline29
Collins JF, Dorus W. Patient selection bias in analyses using only compliant patients. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991:335-48.
30
Fawcett J ,Clark DC ,Aagesen CA , et al. A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry 1987;44:248-256
Web of Science | Medline
- Citing Articles (198)
Citing Articles
1
Craig L. Katz, Didier Jutras-Aswad, Marta Kiliman, Iwona Pilatowicz, Evaristo Akerele, Kathryn Marrone, Fatih Ozbay. (2012) Alcohol Use in Polish 9/11 Responders. Journal of Psychiatric Practice 18:1, 55-63
CrossRef2
Janet K. Coller, Sharon Cahill, Carolyn Edmonds, Aaron L. Farquharson, Marie Longo, Rinaldo Minniti, Thomas Sullivan, Andrew A. Somogyi, Jason M. White. (2011) OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenetics and Genomics 21:12, 902-905
CrossRef3
Maureen T. Cruz, Melissa A. Herman, Marsida Kallupi, Marisa Roberto. (2011) Nociceptin/Orphanin FQ Blockade of Corticotropin-Releasing Factor-Induced Gamma-Aminobutyric Acid Release in Central Amygdala Is Enhanced After Chronic Ethanol Exposure. Biological Psychiatry
CrossRef4
Ismene L Petrakis, Elizabeth Ralevski, Nitigna Desai, Louis Trevisan, Ralitza Gueorguieva, Bruce Rounsaville, John H Krystal. (2011) Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence. Neuropsychopharmacology
CrossRef5
Robert F. Leeman, Marc N. Potenza. (2011) Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology
CrossRef6
Lacey Gunter, Ji Zhu, Susan Murphy. (2011) Variable Selection for Qualitative Interactions in Personalized Medicine While Controlling the Family-Wise Error Rate. Journal of Biopharmaceutical Statistics 21:6, 1063-1078
CrossRef7
Helen M. Pettinati, Bernard L. Silverman, John J. Battisti, Robert Forman, Edward Schweizer, David R. Gastfriend. (2011) Efficacy of Extended-Release Naltrexone in Patients with Relatively Higher Severity of Alcohol Dependence. Alcoholism: Clinical and Experimental Research 35:10, 1804-1811
CrossRef8
Lara A Ray, Spencer Bujarski, Pauline F Chin, Karen Miotto. (2011) Pharmacogenetics of Naltrexone in Asian Americans: A Randomized Placebo-Controlled Laboratory Study. Neuropsychopharmacology
CrossRef9
Raymond F Anton, Raye Z Litten, Daniel E Falk, Joseph M Palumbo, Raymond T Bartus, Rebecca L Robinson, Henry R Kranzler, Thomas R Kosten, Roger E Meyer, Charles P O'Brien, Karl Mann, Didier Meulien. (2011) The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders. Neuropsychopharmacology
CrossRef10
Elaine Setiawan, Robert O. Pihl, Sylvia M. L. Cox, Christina Gianoulakis, Roberta M. Palmour, Chawki Benkelfat, Marco Leyton. (2011) The Effect of Naltrexone on Alcohol’s Stimulant Properties and Self-Administration Behavior in Social Drinkers: Influence of Gender and Genotype. Alcoholism: Clinical and Experimental Research 35:6, 1134-1141
CrossRef11
Gihyun Yoon, Suck Won Kim, Paul Thuras, Joseph Westermeyer. (2011) Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study. Human Psychopharmacology: Clinical and Experimental 26:2, 125-132
CrossRef12
David R. Gastfriend. (2011) Intramuscular extended-release naltrexone: current evidence. Annals of the New York Academy of Sciences 1216:1, 144-166
CrossRef13
Peter M. Miller, Sarah W. Book, Scott H. Stewart. (2011) Medical Treatment of Alcohol Dependence: A Systematic Review. The International Journal of Psychiatry in Medicine 42:3, 227-266
CrossRef14
Susanne Rösner, Andrea Hackl-Herrwerth, Stefan Leucht, Simona Vecchi, Manit Srisurapanont, Michael Soyka, Susanne Rösner. 2010. Opioid antagonists for alcohol dependence. .
CrossRef15
James C. Garbutt, Alexei B. Kampov-Polevoy, Robert Gallop, Linda Kalka-Juhl, Barbara A. Flannery. (2010) Efficacy and Safety of Baclofen for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial. Alcoholism: Clinical and Experimental Research 34:11, 1849-1857
CrossRef16
K. C. Morley, M. Teesson, C. Sannibale, A. Baillie, P. S. Haber. (2010) Clinical Predictors of Outcome from an Australian Pharmacological Relapse Prevention Trial. Alcohol and Alcoholism 45:6, 520-526
CrossRef17
LARA A. RAY, ANDIA HEYDARI, TODD ZORICK. (2010) Quetiapine for the treatment of alcoholism: Scientific rationale and review of the literature. Drug and Alcohol Review 29:5, 568-575
CrossRef18
Christine Yuodelis-Flores, W. Murray Bennett, Charles Meredith, Richard Ries. 2010. Addictive Disorders in Psychiatric Medicine. , 197-218.
CrossRef19
Hugh Myrick, Xingbao Li, Patrick K. Randall, Scott Henderson, Konstantin Voronin, Raymond F. Anton. (2010) The Effect of Aripiprazole on Cue-Induced Brain Activation and Drinking Parameters in Alcoholics. Journal of Clinical Psychopharmacology 30:4, 365-372
CrossRef20
Joshua D. Lee, Ellie Grossman, Danae DiRocco, Andrea Truncali, Kathleen Hanley, David Stevens, John Rotrosen, Marc N. Gourevitch. (2010) Extended-release naltrexone for treatment of alcohol dependence in primary care. Journal of Substance Abuse Treatment 39:1, 14-21
CrossRef21
José Manuel Trigo, Elena Martin-García, Fernando Berrendero, Patricia Robledo, Rafael Maldonado. (2010) The endogenous opioid system: A common substrate in drug addiction. Drug and Alcohol Dependence 108:3, 183-194
CrossRef22
Andreas Heinz, Anne Beck, Jan Mir, Sabine Grüsser, Anthony Grace, Jana Wrase. 2010. Alcohol Craving and Relapse Prediction. , 99-135.
CrossRef23
Shelly F. Greenfield, Alan Shields, Hilary Smith Connery, Viktoriya Livchits, Sergey A. Yanov, Charmaine S. Lastimoso, Aivar K. Strelis, Sergey P. Mishustin, Garrett Fitzmaurice, Trini A. Mathew, Sonya Shin. (2010) Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients: Design and Implementation. Alcoholism: Clinical and Experimental Research 34:2, 317-330
CrossRef24
E. Sherwood Brown, Thomas J. Carmody, Joy M. Schmitz, Raul Caetano, Bryon Adinoff, Alan C. Swann, A. John Rush. (2009) A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Naltrexone in Outpatients With Bipolar Disorder and Alcohol Dependence. Alcoholism: Clinical and Experimental Research 33:11, 1863-1869
CrossRef25
Sarah H. Heil, Teresa Linares Scott, Stephen T. Higgins. (2009) An overview of principles of effective treatment of substance use disorders and their potential application to pregnant cigarette smokers. Drug and Alcohol Dependence 104, S106-S114
CrossRef26
Richard Longabaugh, Philip W. Wirtz, Suzy Bird Gulliver, Dena Davidson. (2009) Extended naltrexone and broad spectrum treatment or motivational enhancement therapy. Psychopharmacology 206:3, 367-376
CrossRef27
Hugh Myrick, Robert Malcolm, Patrick K. Randall, Elizabeth Boyle, Raymond F. Anton, Howard C. Becker, Carrie L. Randall. (2009) A Double-Blind Trial of Gabapentin Versus Lorazepam in the Treatment of Alcohol Withdrawal. Alcoholism: Clinical and Experimental Research 33:9, 1582-1588
CrossRef28
Amir H. Rezvani, David H. Overstreet, Anil H. Vaidya, Boyu Zhao, Edward D. Levin. (2009) Carisbamate, a Novel Antiepileptic Candidate Compound, Attenuates Alcohol Intake in Alcohol-Preferring Rats. Alcoholism: Clinical and Experimental Research 33:8, 1366-1373
CrossRef29
Joel Gelernter, Henry R. Kranzler. (2009) Genetics of alcohol dependence. Human Genetics 126:1, 91-99
CrossRef30
Keith D. Lindor, M. Eric Gershwin, Raoul Poupon, Marshall Kaplan, Nora V. Bergasa, E. Jenny Heathcote. (2009) Primary biliary cirrhosis. Hepatology 50:1, 291-308
CrossRef31
Xinguang Chen, Sonja Lunn, Lynette Deveaux, Xiaoming Li, Nanika Brathwaite, Lesley Cottrell, Bonita Stanton. (2009) A Cluster Randomized Controlled Trial of an Adolescent HIV Prevention Program Among Bahamian Youth: Effect at 12 Months Post-Intervention. AIDS and Behavior 13:3, 499-508
CrossRef32
B. Bie, W. Zhu, Z.Z. Pan. (2009) Ethanol-induced delta-opioid receptor modulation of glutamate synaptic transmission and conditioned place preference in central amygdala. Neuroscience 160:2, 348-358
CrossRef33
Michael R. Lucey. (2009) Management of Alcoholic Liver Disease. Clinics in Liver Disease 13:2, 267-275
CrossRef34
KIRSTEN C. MORLEY, MAREE TEESSON, CLAUDIA SANNIBALE, PAUL S. HABER. (2009) Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence. Drug and Alcohol Review 28:3, 222-229
CrossRef35
Karl Mann, Falk Kiefer, Michael Smolka, Horst Gann, Stefan Wellek, Andreas Heinz, . (2009) Searching for Responders to Acamprosate and Naltrexone in Alcoholism Treatment: Rationale and Design of the Predict Study. Alcoholism: Clinical and Experimental Research 33:4, 674-683
CrossRef36
Filippo Passetti, Colin Drummond. 2009. Alcohol-Use Disorders - Treatment and Management. , 147-173.
CrossRef37
Gabor Oroszi, Raymond F. Anton, Stephanie O’Malley, Robert Swift, Helen Pettinati, David Couper, Qiaoping Yuan, David Goldman. (2009) OPRM1 Asn40Asp Predicts Response to Naltrexone Treatment: A Haplotype-Based Approach. Alcoholism: Clinical and Experimental Research 33:3, 383-393
CrossRef38
Isto Nordback, Hanna Pelli, Riitta Lappalainen–Lehto, Satu Järvinen, Sari Räty, Juhani Sand. (2009) The Recurrence of Acute Alcohol-Associated Pancreatitis Can Be Reduced: A Randomized Controlled Trial. Gastroenterology 136:3, 848-855
CrossRef39
James R. McKay. (2009) Continuing care research: What we have learned and where we are going. Journal of Substance Abuse Treatment 36:2, 131-145
CrossRef40
Lara A. Ray, James MacKillop, Lorenzo Leggio, Marilee Morgan, Kent E. Hutchison. (2009) Effects of naltrexone on cortisol levels in heavy drinkers. Pharmacology Biochemistry and Behavior 91:4, 489-494
CrossRef41
Helen M. Pettinati, David R. Gastfriend, Qunming Dong, Henry R. Kranzler, Stephanie S. O’Malley. (2009) Effect of Extended-Release Naltrexone (XR-NTX) on Quality of Life in Alcohol-Dependent Patients. Alcoholism: Clinical and Experimental Research 33:2, 350-356
CrossRef42
Michael P. Bogenschutz, J. Scott Tonigan, Helen M. Pettinati. (2009) Effects of Alcoholism Typology on Response to Naltrexone in the COMBINE Study. Alcoholism: Clinical and Experimental Research 33:1, 10-18
CrossRef43
Robert Swift, Lorenzo Leggio. 2009. Adjunctive Pharmacotherapy in the Treatment of Alcohol and Drug Dependence. , 287-310.
CrossRef44
Andreas Heinz, Anne Beck, Sabine M. Grüsser, Anthony A. Grace, Jana Wrase. (2009) Identifying the neural circuitry of alcohol craving and relapse vulnerability. Addiction Biology 14:1, 108-118
CrossRef45
Sung-Gon Kim, Cheol-Min Kim, Sam-Wook Choi, Young-Myo Jae, Hae-Gook Lee, Bong-Ki Son, Jeong-Gee Kim, Young-Sung Choi, Han-Oh Kim, Seong-Yeon Kim, David W. Oslin. (2009) A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology 201:4, 611-618
CrossRef46
(2008) Denying autonomy in order to create it: the paradox of forcing treatment upon addicts. Addiction 103:12, 1919-1921
CrossRef47
Q. Li, Y. Okada, E. Marczak, W. A. Wilson, L. H. Lazarus, H. S. Swartzwelder. (2008) The Novel -Opioid Receptor Antagonist, [N-Allyl-Dmt1]Endomorphin-2, Attenuates the Enhancement of GABAergic Neurotransmission by Ethanol. Alcohol and Alcoholism 44:1, 13-19
CrossRef48
Jon E. Grant, Suck Won Kim, Eric Hollander, Marc N. Potenza. (2008) Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology 200:4, 521-527
CrossRef49
Keith L. Williams, Jasmine S. Schimmel. (2008) Effect of naltrexone during extinction of alcohol-reinforced responding and during repeated cue-conditioned reinstatement sessions in a cue exposure style treatment. Alcohol 42:7, 553-563
CrossRef50
S Paul Berger. (2008) Brain science and addiction. The Lancet 372:9646, 1280-1281
CrossRef51
Ilana Roth-Deri, Tamar Green-Sadan, Gal Yadid. (2008) β-Endorphin and drug-induced reward and reinforcement. Progress in Neurobiology 86:1, 1-21
CrossRef52
Ellen M. Unterwald. (2008) Naltrexone in the Treatment of Alcohol Dependence. Journal of Addiction Medicine 2:3, 121-127
CrossRef53
Francheska Perepletchikova, John H. Krystal, Joan Kaufman. (2008) Practitioner Review: Adolescent alcohol use disorders: assessment and treatment issues. Journal of Child Psychology and Psychiatry
CrossRef54
Anton, Raymond F., . (2008) Naltrexone for the Management of Alcohol Dependence. New England Journal of Medicine 359:7, 715-721
Full Text55
Albert J. Arias, Stephen Armeli, Joel Gelernter, Jonathan Covault, Antero Kallio, Sakari Karhuvaara, Tiina Koivisto, Rauno Mkel, Henry R. Kranzler. (2008) Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers. Alcoholism: Clinical and Experimental Research 32:7, 1159-1166
CrossRef56
David W. Oslin, Kevin G. Lynch, Helen M. Pettinati, Kyle M. Kampman, Peter Gariti, Lois Gelfand, Thomas Ten Have, Shoshana Wortman, William Dundon, Charles Dackis, Joseph R. Volpicelli, Charles P. OBrien. (2008) A Placebo-Controlled Randomized Clinical Trial of Naltrexone in the Context of Different Levels of Psychosocial Intervention. Alcoholism: Clinical and Experimental Research 32:7, 1299-1308
CrossRef57
Carrie B. Oser, Paul M. Roman. (2008) A categorical typology of naltrexone-adopting private substance abuse treatment centers. Journal of Substance Abuse Treatment 34:4, 433-442
CrossRef58
Helen M. Pettinati, Kyle M. Kampman, Kevin G. Lynch, Jesse J. Suh, Charles A. Dackis, David W. Oslin, Charles P. O'Brien. (2008) Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. Journal of Substance Abuse Treatment 34:4, 378-390
CrossRef59
Wade Berrettini. (2008) Naltrexone Pharmacogenetics in Alcohol-Dependent Patients. Psychiatric Annals 38:6, 408-412
CrossRef60
Anders Bergmark. (2008) On treatment mechanisms-what can we learn from the COMBINE study?. Addiction 103:5, 703-705
CrossRef61
P. Perney, H. Rigole, F. Blanc. (2008) Alcoolodépendance : diagnostic et traitement. La Revue de Médecine Interne 29:4, 297-304
CrossRef62
J. Luty, T. Carnwath. (2008) Specialised alcohol treatment services are a luxury the NHS cannot afford. The British Journal of Psychiatry 192:4, 245-247
CrossRef63
Falk Kiefer, Miguel Angel Jiménez-Arriero, Oliver Klein, Alexander Diehl, Gabriel Rubio. (2008) Cloninger’s typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone. Addiction Biology 13:1, 124-129
CrossRef64
Nora V. Bergasa. (2008) Update on the Treatment of the Pruritus of Cholestasis. Clinics in Liver Disease 12:1, 219-234
CrossRef65
Jennifer W. Tidey, Peter M. Monti, Damaris J. Rohsenow, Chad J. Gwaltney, Robert Miranda, John E. McGeary, James MacKillop, Robert M. Swift, David B. Abrams, Saul Shiffman, Jean A. Paty. (2008) Moderators of Naltrexone’s Effects on Drinking, Urge, and Alcohol Effects in Non-Treatment-Seeking Heavy Drinkers in the Natural Environment. Alcoholism: Clinical and Experimental Research 32:1, 58-66
CrossRef66
John H. Krystal, Ralitza Gueorguieva, Joyce Cramer, Joseph Collins, Robert Rosenheck, . (2008) Naltrexone Is Associated With Reduced Drinking by Alcohol Dependent Patients Receiving Antidepressants for Mood and Anxiety Symptoms: Results From VA Cooperative Study No. 425, “Naltrexone in the Treatment of Alcoholism”. Alcoholism: Clinical and Experimental Research 32:1, 85-91
CrossRef67
Fabio Caputo, Giovanni Addolorato, Michela Stoppo, Sara Francini, Teo Vignoli, Francesca Lorenzini, Arfedele Del Re, Claudio Comaschi, Pietro Andreone, Franco Trevisani, Mauro Bernardi, Alcohol Treatment Study Group. (2007) Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: An open randomised comparative study. European Neuropsychopharmacology 17:12, 781-789
CrossRef68
Paolo Mannelli, Kathleen Peindl, Prakash S Masand, Ashwin A Patkar. (2007) Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Review of Neurotherapeutics 7:10, 1265-1277
CrossRef69
Carmen S van der Zwaluw, Esther van den Wildenberg, Reinout W Wiers, Barbara Franke, Jan Buitelaar, Ron HJ Scholte, Rutger CME Engels. (2007) Polymorphisms in the µ-opioid receptor gene ( OPRM1 ) and the implications for alcohol dependence in humans. Pharmacogenomics 8:10, 1427-1436
CrossRef70
Dena Davidson, Philip W. Wirtz, Suzy Bird Gulliver, Richard Longabaugh. (2007) Naltrexone’s suppressant effects on drinking are limited to the first 3 months of treatment. Psychopharmacology 194:1, 1-10
CrossRef71
Sawitri Assanangkornchai, Manit Srisurapanont. (2007) The treatment of alcohol dependence. Current Opinion in Internal Medicine 6:4, 402-407
CrossRef72
Sakari Karhuvaara, Kaarlo Simojoki, Antti Virta, Markus Rosberg, Eliisa Löyttyniemi, Tommi Nurminen, Antero Kallio, Rauno Mäkelä. (2007) Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double-Blind Placebo-Controlled Multicenter Study. Alcoholism: Clinical and Experimental Research 31:7, 1179-1187
CrossRef73
Wendy Ooteman, Maarten W.J. Koeter, Roel Verheul, Gerard M. Schippers, Wim van den Brink. (2007) The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. European Neuropsychopharmacology 17:8, 558-566
CrossRef74
Jakob Hein, Michael Rapp, Andreas Heinz. (2007) Alkoholbedingte Störungen – ein kleines Alphabet der Neurobiologie. Psychiatrie und Psychotherapie 3:2, 45-49
CrossRef75
Ralitza Gueorguieva, Ran Wu, Brian Pittman, Joyce Cramer, Robert A. Rosenheck, Stephanie S. O’Malley, John H. Krystal. (2007) New Insights into the Efficacy of Naltrexone Based on Trajectory-Based Reanalyses of Two Negative Clinical Trials. Biological Psychiatry 61:11, 1290-1295
CrossRef76
Karl Mann. (2007) Neue Ansätze in Diagnostik und Behandlung von Alkoholproblemen. Psychiatrie und Psychotherapie 3:2, 51-56
CrossRef77
Boukje A. G. Dijkstra, Cor A. J. De Jong, Sarah M. Bluschke, Paul F. M. Krabbe, Cees P. F. van der Staak. (2007) Does naltrexone affect craving in abstinent opioid-dependent patients?. Addiction Biology 12:2, 176-182
CrossRef78
Mitchell P. Karno, Richard Longabaugh. (2007) Does matching matter? Examining matches and mismatches between patient attributes and therapy techniques in alcoholism treatment. Addiction 102:4, 587-596
CrossRef79
Thomas P Beresford, Brandon Martin. (2007) The evidence for drug treatment of alcohol dependence in liver transplant patients. Current Opinion in Organ Transplantation 12:2, 176-181
CrossRef80
Jaakko Lappalainen, Evgeny Krupitsky, Henry R. Kranzler, Xingguang Luo, Mikhail Remizov, Sofia Pchelina, Anastaisa Taraskina, Edwin Zvartau, Pirkko Räsanen, Taru Makikyro, Lucia K. Somberg, John H. Krystal, Murray B. Stein, Joel Gelernter. (2007) Mutation screen of theGAD2 gene and association study of alcoholism in three populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 144B:2, 183-192
CrossRef81
Joel Gelernter, Ralitza Gueorguieva, Henry R. Kranzler, Huiping Zhang, Joyce Cramer, Robert Rosenheck, John H. Krystal, . (2007) Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study. Alcoholism: Clinical and Experimental Research 0:0, 070212174136005-???
CrossRef82
Darin J. Knapp, David H. Overstreet, George R. Breese. (2007) Baclofen Blocks Expression and Sensitization of Anxiety-Like Behavior in an Animal Model of Repeated Stress and Ethanol Withdrawal. Alcoholism: Clinical and Experimental Research 0:0, 070212174136006-???
CrossRef83
Sophie Tambour, Etienne Quertemont. (2007) Preclinical and clinical pharmacology of alcohol dependence. Fundamental & Clinical Pharmacology 21:1,
CrossRef84
Jennifer M Mitchell, Venessa C Tavares, Howard L Fields, Mark D'Esposito, Charlotte A Boettiger. (2007) Endogenous Opioid Blockade and Impulsive Responding in Alcoholics and Healthy Controls. Neuropsychopharmacology 32:2, 439-449
CrossRef85
Roberto Ciccocioppo, Daina Economidou, Roberto Rimondini, Wolfgang Sommer, Maurizio Massi, Markus Heilig. (2007) Buprenorphine Reduces Alcohol Drinking Through Activation of the Nociceptin/Orphanin FQ-NOP Receptor System. Biological Psychiatry 61:1, 4-12
CrossRef86
Keith L. Williams. (2007) Development of Naltrexone Supersensitivity During Food-Maintained Responding Enhances Naltrexone's Ability to Reduce Ethanol-Maintained Responding. Alcoholism: Clinical and Experimental Research 31:1, 39-47
CrossRef87
A. Diehl, K. Mann. (2007) Pharmakologische Rückfallprävention bei Alkohol- und Tabakabhängigkeit. Der Internist 48:1, 79-88
CrossRef88
2007. A. , 3-25.
CrossRef89
John C.M. Brust. 2007. Éthanol. , 385-516.
CrossRef90
Michael Soyka, Susanne Roesner. (2006) New pharmacological approaches for the treatment of alcoholism. Expert Opinion on Pharmacotherapy 7:17, 2341-2353
CrossRef91
Ismene L. Petrakis. (2006) A Rational Approach to the Pharmacotherapy of Alcohol Dependence. Journal of Clinical Psychopharmacology 26:Supplement 1, S3-S12
CrossRef92
Helen M. Pettinati, Charles P. O'Brien, Amanda R. Rabinowitz, Shoshana P. Wortman, David W. Oslin, Kyle M. Kampman, Charles A. Dackis. (2006) The Status of Naltrexone in the Treatment of Alcohol Dependence. Journal of Clinical Psychopharmacology 26:6, 610-625
CrossRef93
Roger D. Weiss, Karsten D. Kueppenbender. (2006) Combining Psychosocial Treatment with Pharmacotherapy for Alcohol Dependence. Journal of Clinical Psychopharmacology 26:Supplement 1, S37-S42
CrossRef94
Richard N. Rosenthal. (2006) Current and Future Drug Therapies for Alcohol Dependence. Journal of Clinical Psychopharmacology 26:Supplement 1, S20-S29
CrossRef95
James R. McKay. (2006) Continuing care in the treatment of addictive disorders. Current Psychiatry Reports 8:5, 355-362
CrossRef96
Sheila A Doggrell. (2006) Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?. Expert Opinion on Pharmacotherapy 7:15, 2169-2173
CrossRef97
Kirsten C. Morley, Maree Teesson, Sophie C. Reid, Claudia Sannibale, Clare Thomson, Nghi Phung, Martin Weltman, James R. Bell, Kylie Richardson, Paul S. Haber. (2006) Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 101:10, 1451-1462
CrossRef98
David H. Overstreet, Amir H. Rezvani, Michael Cowen, Feng Chen, Andrew J. Lawrence. (2006) Modulation of high alcohol drinking in the inbred Fawn?Hooded (FH/Wjd) rat strain: implications for treatment. Addiction Biology 11:3-4, 356-373
CrossRef99
Nassima Ait-Daoud, Robert J. Malcolm, Bankole A. Johnson. (2006) An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addictive Behaviors 31:9, 1628-1649
CrossRef100
D. J. Fachin-Scheit, A. Frozino Ribeiro, G. Pigatto, F. Oliveira Goeldner, R. Boerngen de Lacerda. (2006) Development of a mouse model of ethanol addiction: naltrexone efficacy in reducing consumption but not craving. Journal of Neural Transmission 113:9, 1305-1321
CrossRef101
John H. Krystal, D. Cyril D’Souza, JÜrgen Gallinat, Naomi Driesen, Anissa Abi-Dargham, Ismene Petrakis, Andreas Heinz, Godfrey Pearlson. (2006) The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotoxicity Research 10:3-4, 235-252
CrossRef102
Elizabeth Ralevski, Krishna Balachandra, Ralitza Gueorguieva, Diana Limoncelli, Ismene Petrakis. (2006) Effects of Naltrexone on Cognition in a Treatment Study of Patients with Schizophrenia and Comorbid Alcohol Dependence. Journal of Dual Diagnosis 2:4, 53-69
CrossRef103
John H Krystal, Steven Madonick, Edward Perry, Ralitza Gueorguieva, Laura Brush, Yola Wray, Aysenil Belger, Deepak Cyril D'Souza. (2006) Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism. Neuropsychopharmacology 31:8, 1793-1800
CrossRef104
Hendrik G. Roozen, Ranne de Waart, Danielle A.W.M. van der Windt, Wim van den Brink, Cor A.J. de Jong, Ad J.F.M. Kerkhof. (2006) A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. European Neuropsychopharmacology 16:5, 311-323
CrossRef105
Kee Namkoong. (2006) Pharmacotherapeutic Interventions to Maintaining Abstinence in Alcoholism. Journal of the Korean Medical Association 49:2, 134
CrossRef106
Young-Chul Jung, Kee Namkoong. (2006) Pharmacotherapy for Alcohol Dependence: Anticraving Medications for Relapse Prevention. Yonsei Medical Journal 47:2, 167
CrossRef107
K. Mann, K. Ackermann, A. Diehl, D. Ebert, G. Mundle, H. Nakovics, T. Reker, G. Richter, L. G. Schmidt, M. Driessen, K. Rettig, K. Opitz, B. Croissant. (2006) Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. Psychopharmacology 184:1, 115-121
CrossRef108
Falk Kiefer, Karl Mann. (2005) New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. European Journal of Pharmacology 526:1-3, 163-171
CrossRef109
Mark Egli. (2005) Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?. Addiction Biology 10:4, 309-319
CrossRef110
Kimmo Ingman, Nora Hagelberg, Sargo Aalto, Kjell Någren, Auni Juhakoski, Sakari Karhuvaara, Antero Kallio, Vesa Oikonen, Jarmo Hietala, Harry Scheinin. (2005) Prolonged Central μ-Opioid Receptor Occupancy after Single and Repeated Nalmefene Dosing. Neuropsychopharmacology 30:12, 2245-2253
CrossRef111
Xing Dai, Joseph Thavundayil, Christina Gianoulakis. (2005) Differences in the Peripheral Levels of ??-endorphin in Response to Alcohol and Stress as a Function of Alcohol Dependence and Family History of Alcoholism. Alcoholism: Clinical & Experimental Research 29:11, 1965-1975
CrossRef112
James R. McKay. (2005) Is there a case for extended interventions for alcohol and drug use disorders?. Addiction 100:11, 1594-1610
CrossRef113
I. L. Petrakis, C. Nich, E. Ralevski. (2005) Psychotic Spectrum Disorders and Alcohol Abuse: A Review of Pharmacotherapeutic Strategies and a Report on the Effectiveness of Naltrexone and Disulfiram. Schizophrenia Bulletin 32:4, 644-654
CrossRef114
Barbara J Mason. (2005) Acamprosate in the treatment of alcohol dependence. Expert Opinion on Pharmacotherapy 6:12, 2103-2115
CrossRef115
Ming-Chyi Huang, Chun-Hsin Chen, Jeng-Ming Yu, Chiao-Chicy Chen. (2005) A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan. Addiction Biology 10:3, 289-292
CrossRef116
Raymond F. Anton, Darlene H. Moak, Patricia Latham, L. Randolph Waid, Hugh Myrick, Konstantin Voronin, Angelica Thevos, Wei Wang, Robert Woolson. (2005) Naltrexone Combined With Either Cognitive Behavioral or Motivational Enhancement Therapy for Alcohol Dependence. Journal of Clinical Psychopharmacology 25:4, 349-357
CrossRef117
Richard Feinn, Henry R. Kranzler. (2005) Does Effect Size in Naltrexone Trials for Alcohol Dependence Differ for Single-Site vs. Multi-Center Studies?. Alcoholism: Clinical & Experimental Research 29:6, 983-988
CrossRef118
Raye Z Litten, Joanne Fertig, Margaret Mattson, Mark Egli. (2005) Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opinion on Emerging Drugs 10:2, 323-343
CrossRef119
Ismene L. Petrakis, James Poling, Carolyn Levinson, Charla Nich, Kathleen Carroll, Bruce Rounsaville. (2005) Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Psychiatric Disorders. Biological Psychiatry 57:10, 1128-1137
CrossRef120
Jason P. Schroeder, David H. Overstreet, Clyde W. Hodge. (2005) The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats. Psychopharmacology 179:1, 262-270
CrossRef121
George R. Breese, David H. Overstreet, Darin J. Knapp. (2005) Conceptual framework for the etiology of alcoholism: a ?kindling?/stress hypothesis. Psychopharmacology 178:4, 367-380
CrossRef122
M. Hautzinger, H. Wetzel, A. Szegedi, A. Scheurich, B. L
rch, P. Singer, D. Schl
CrossRef123
Saitz, Richard, . (2005) Unhealthy Alcohol Use. New England Journal of Medicine 352:6, 596-607
Full Text124
Manit Srisurapanont, Ngamwong Jarusuraisin, Manit Srisurapanont. 2005. Opioid antagonists for alcohol dependence. .
CrossRef125
Vania Modesto-Lowe, Eleanor M Fritz. (2005) The Opioidergic-Alcohol Link. CNS Drugs 19:8, 693-707
CrossRef126
Giovanni Addolorato, Ludovico Abenavoli, Lorenzo Leggio, Giovanni Gasbarrini. (2005) How Many Cravings? Pharmacological Aspects of Craving Treatment in Alcohol Addiction: A Review. Neuropsychobiology 51:2, 59-66
CrossRef127
Robert B. Cutler. (2005) Abatement of craving in recovering alcoholics: A descriptive analysis. Addiction Research & Theory 13:2, 111-127
CrossRef128
Alessandra Buonopane, Ismene L. Petrakis. (2005) Pharmacotherapy of Alcohol Use Disorders. Substance Use & Misuse 40:13-14, 2001-2020
CrossRef129
Falk Kiefer, Hauke Helwig, Timo Tarnaske, Christian Otte, Holger Jahn, Klaus Wiedemann. (2005) Pharmacological Relapse Prevention of Alcoholism: Clinical Predictors of Outcome. European Addiction Research 11:2, 83-91
CrossRef130
William F. Rayburn, Michael P. Bogenschutz. (2004) Pharmacotherapy for pregnant women with addictions. American Journal of Obstetrics and Gynecology 191:6, 1885-1897
CrossRef131
M SOFUOGLU, T KOSTEN. (2004) Pharmacologic management of relapse prevention in addictive disorders. Psychiatric Clinics of North America 27:4, 627-648
CrossRef132
Therese K. Killeen, Kathleen T. Brady, Paul B. Gold, Kit N. Simpson, Richard A. Faldowski, Clare Tyson, Raymond F. Anton. (2004) Effectiveness of Naltrexone in a Community Treatment Program. Alcoholism: Clinical & Experimental Research 28:11, 1710-1717
CrossRef133
Darlene H Moak. (2004) Assessing the efficacy of medical treatments for alcohol use disorders. Expert Opinion on Pharmacotherapy 5:10, 2075-2089
CrossRef134
Barbara A. Flannery, James C. Garbutt, Meghan W. Cody, William Renn, Kathy Grace, Michael Osborne, Ken Crosby, Mary Morreale, Amy Trivette. (2004) Baclofen for Alcohol Dependence: A Preliminary Open-Label Study. Alcoholism: Clinical & Experimental Research 28:10, 1517-1523
CrossRef135
F. Kiefer, F. Andersohn, C. Otte, K. Wolf, H. Jahn, K. Wiedemann. (2004) Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence. Acta Neuropsychiatrica 16:5, 233-238
CrossRef136
Katherine M. Harris, Cindy Thomas. (2004) Naltrexone and Pharmacy Benefit Management. Journal of Addictive Diseases 23:4, 11-29
CrossRef137
Bankole A Johnson. (2004) An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert Opinion on Pharmacotherapy 5:9, 1943-1955
CrossRef138
David J. Drobes, Raymond F. Anton, Suzanne E. Thomas, Konstantin Voronin. (2004) Effects of Naltrexone and Nalmefene on Subjective Response to Alcohol Among Non-Treatment-Seeking Alcoholics and Social Drinkers. Alcoholism: Clinical & Experimental Research 28:9, 1362-1370
CrossRef139
Bankole A. Johnson, Nassima Ait-Daoud, Henri-Jean Aubin, Wim van den Brink, Richard Guzzetta, John Loewy, Bernard Silverman, Elliot Ehrich. (2004) A Pilot Evaluation of the Safety and Tolerability of Repeat Dose Administration of Long-Acting Injectable Naltrexone (Vivitrex??) in Patients With Alcohol Dependence. Alcoholism: Clinical & Experimental Research 28:9, 1356-1361
CrossRef140
Iain S. McGregor, Jason E. Gallate. (2004) Rats on the grog: Novel pharmacotherapies for alcohol craving. Addictive Behaviors 29:7, 1341-1357
CrossRef141
Lauren C. Costantini, Sofie R. Kleppner, Joseph McDonough, Marc R. Azar, Raj Patel. (2004) Implantable technology for long-term delivery of nalmefene for treatment of alcoholism. International Journal of Pharmaceutics 283:1-2, 35-44
CrossRef142
Hugh Myrick, Raymond Anton. (2004) Recent advances in the pharmacotherapy of alcoholism. Current Psychiatry Reports 6:5, 332-338
CrossRef143
Michael F. Stromberg. (2004) The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat. Pharmacology Biochemistry and Behavior 78:4, 743-750
CrossRef144
Raymond F. Anton, Helen Pettinati, Allen Zweben, Henry R. Kranzler, Bankole Johnson, Michael J. Bohn, Mary E. McCaul, Robert Anthenelli, Ihsan Salloum, Gantt Galloway, James Garbutt, Robert Swift, David Gastfriend, Antero Kallio, Sakari Karhuvaara. (2004) A Multi-site Dose Ranging Study of Nalmefene in the Treatment of Alcohol Dependence. Journal of Clinical Psychopharmacology 24:4, 421-428
CrossRef145
John A. Hermos, Melissa M. Young, David R. Gagnon, Louis D. Fiore. (2004) Patterns of Dispensed Disulfiram and Naltrexone for Alcoholism Treatment in a Veteran Patient Population. Alcoholism: Clinical & Experimental Research 28:8, 1229-1235
CrossRef146
Dena Davidson, Chandan Saha, Stephanie Scifres, Joanne Fyffe, Sean O'Connor, Christopher Selzer. (2004) Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers. Addictive Behaviors 29:6, 1253-1258
CrossRef147
Bouza Carmen, Magro Angeles, Muñoz Ana, Amate José María. (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99:7, 811-828
CrossRef148
Henry R. Kranzler, Donald R. Wesson, Laurent Billot. (2004) Naltrexone Depot for Treatment of Alcohol Dependence: A Multicenter, Randomized, Placebo-Controlled Clinical Trial. Alcoholism: Clinical & Experimental Research 28:7, 1051-1059
CrossRef149
Jack R. Cornelius, Duncan B. Clark, Ihsan M. Salloum, Oscar G. Bukstein, Thomas M. Kelly. (2004) Interventions in Suicidal Alcoholics. Alcoholism: Clinical and Experimental Research 28, 89S-96S
CrossRef150
Nora V. Bergasa. (2004) Treatment of the pruritus of cholestasis: From unbearable lightness to substance. Hepatology 39:5, 1450-1453
CrossRef151
L.M Oswald, G.S Wand. (2004) Opioids and alcoholism. Physiology & Behavior 81:2, 339-358
CrossRef152
Mark L Willenbring, Daniel Kivlahan, Marie Kenny, Michael Grillo, Hildi Hagedorn, Andrea Postier. (2004) Beliefs about evidence-based practices in addiction treatment: A survey of Veterans Administration program leaders. Journal of Substance Abuse Treatment 26:2, 79-85
CrossRef153
Ismene L. Petrakis, Stephanie O’Malley, Bruce Rounsaville, James Poling, Colette McHugh-Strong, John H. Krystal, . (2004) Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 172:3, 291-297
CrossRef154
Badreddine Bencherif, Gary S Wand, Mary E McCaul, Yu Kyeong Kim, Nese Ilgin, Robert F Dannals, James J Frost. (2004) Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biological Psychiatry 55:3, 255-262
CrossRef155
Peter M. Monti, Jennifer Tidey, Cristine L. Czachowski, Kathleen A. Grant, Damaris J. Rohsenow, Michael Sayette, Natalie Maners, Peter Pierre. (2004) Building Bridges: The Transdisciplinary Study of Craving From the Animal Laboratory to the Lamppost. Alcoholism: Clinical & Experimental Research 28:2, 279-287
CrossRef156
SUNG-GON KIM, BYEUNG-DEUK HAN, JE-MIN PARK, MYUNG-JUNG KIM, MICHAEL F. STROMBERG. (2004) Effect of the combination of naltrexone and acamprosate on alcohol intake in mice. Psychiatry and Clinical Neurosciences 58:1, 30-36
CrossRef157
Bankole A. Johnson, Robert M. Swift, Nassima Ait-Daoud, Carlo C. DiClemente, Martin A. Javors, Robert J. Malcolm. (2004) Development of Novel Pharmacotherapies for the Treatment of Alcohol Dependence: Focus on Antiepileptics. Alcoholism: Clinical & Experimental Research 28:2, 295-301
CrossRef158
Henry R. Kranzler, Stephen Armeli, Richard Feinn, Howard Tennen. (2004) Targeted Naltrexone Treatment Moderates the Relations Between Mood and Drinking Behavior Among Problem Drinkers.. Journal of Consulting and Clinical Psychology 72:2, 317-327
CrossRef159
Nora V. Bergasa. (2004) Pruritus in chronic liver disease: Mechanisms and treatment. Current Gastroenterology Reports 6:1, 10-16
CrossRef160
Karl Mann. (2004) Pharmacotherapy of Alcohol Dependence. CNS Drugs 18:8, 485-504
CrossRef161
Gerald F. X. Feeney, Gerald F. X. Feeney, Jason P Connor, Ross Mc.D Young, Jane Tucker, Annie Mcpherson. (2004) Alcohol dependence: the impact of cognitive behaviour therapy with or without naltrexone on subjective health status. Australian and New Zealand Journal of Psychiatry 38:10, 842-848
CrossRef162
Damaris J Rohsenow. (2004) What Place Does Naltrexone Have in the Treatment of Alcoholism?. CNS Drugs 18:9, 547-560
CrossRef163
Barbara J. Mason. (2003) Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. European Neuropsychopharmacology 13:6, 469-475
CrossRef164
Ismene L. Petrakis, Douglas Leslie, Robert Rosenheck. (2003) Use of Naltrexone in the Treatment of Alcoholism Nationally in the Department of Veterans Affairs. Alcoholism: Clinical & Experimental Research 27:11, 1780-1784
CrossRef165
Wing Ming Keung. (2003) Anti-dipsotropic isoflavones: The potential therapeutic agents for alcohol dependence. Medicinal Research Reviews 23:6, 669-696
CrossRef166
Mats Berglund, Sten Thelander, Mikko Salaspuro, Johan Franck, Sven Andr??asson, Agneta ??jehagen. (2003) Treatment of Alcohol Abuse: An Evidence-Based Review. Alcoholism: Clinical & Experimental Research 27:10, 1645-1656
CrossRef167
Camí, Jordi, Farré, Magí, . (2003) Drug Addiction. New England Journal of Medicine 349:10, 975-986
Full Text168
Joyce Cramer, Robert Rosenheck, Gail Kirk, William Krol, John Krystal. (2003) Medication Compliance Feedback and Monitoring in a Clinical Trial: Predictors and Outcomes. Value in Health 6:5, 566-573
CrossRef169
M BOGENSCHUTZ, C GEPPERT. (2003) Pharmacologic treatments for women with addictions. Obstetrics and Gynecology Clinics of North America 30:3, 523-544
CrossRef170
Alisdair Mackenzie, Richard P. Allen. (2003) Alcoholics' Evaluations of Alcoholism Treatment. Alcoholism Treatment Quarterly 21:2, 1-18
CrossRef171
Jon E. Grant, Suck Won Kim, Marc N. Potenza, Carlos Blanco, Angela Ibanez, Lee Stevens, Joel M. Hektner, Rocco Zaninelli. (2003) Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. International Clinical Psychopharmacology 18:4, 243-249
CrossRef172
(2003) Testing Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (The COMBINE Study): A Pilot Feasibility Study. Alcoholism: Clinical & Experimental Research 27:7, 1123-1131
CrossRef173
Tami L. Mark, Joffre Swait. (2003) Using Stated Preference Modeling to Forecast the Effect of Medication Attributes on Prescriptions of Alcoholism Medications. Value in Health 6:4, 474-482
CrossRef174
(2003) Testing Combined Pharmacotherapies and Behavioral Interventions in Alcohol Dependence: Rationale and Methods. Alcoholism: Clinical and Experimental Research 27:7, 1107-1122
CrossRef175
John H. Krystal, Ismene L. Petrakis, Graeme Mason, Louis Trevisan, D.Cyril D'Souza. (2003) N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacology & Therapeutics 99:1, 79-94
CrossRef176
J. Balldin, M. Berglund, S. Borg, Marianne M??nsson, P. Bendtsen, J. Franck, L. Gustafsson, J. Halldin, L.- H. Nilsson, G. Stolt, A. Willander. (2003) A 6-Month Controlled Naltrexone Study: Combined Effect With Cognitive Behavioral Therapy in Outpatient Treatment of Alcohol Dependence. Alcoholism: Clinical & Experimental Research 27:7, 1142-1149
CrossRef177
Henry R. Kranzler, Stephen Armeli, Howard Tennen, Ola Blomqvist, Cheryl Oncken, Nancy Petry, Richard Feinn. (2003) Targeted Naltrexone for Early Problem Drinkers. Journal of Clinical Psychopharmacology 23:3, 294-304
CrossRef178
Michael Soyka, Jonathan Chick. (2003) Use of Acamprosate and Opioid Antagonists in the Treatment of Alcohol Dependence: A European Perspective. The American Journal on Addictions 12, s69-s80
CrossRef179
Mary E. McCaul, Nancy M. Petry. (2003) The Role of Psychosocial Treatments in Pharmacotherapy for Alcoholism. The American Journal on Addictions 12, s41-s52
CrossRef180
Raymond F. Anton, Robert M. Swift. (2003) Current Pharmacotherapies of Alcoholism: A U.S. Perspective. The American Journal on Addictions 12, s53-s68
CrossRef181
F. Caputo, G. Addolorato, F. Lorenzini, M. Domenicali, G. Greco, A. del RE, G. Gasbarrini, G.F. Stefanini, M. Bernardi. (2003) Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug and Alcohol Dependence 70:1, 85-91
CrossRef182
Tami L. Mark, Henry R. Kranzler, Xue Song, Peace Bransberger, Virginia H. Poole, Scott Crosse. (2003) Physicians' opinions about medications to treat alcoholism. Addiction 98:5, 617-626
CrossRef183
AVRAM H. MACK, RICHARD J. FRANCES. (2003) Treatment of Alcohol Use Disorders in Adolescents. Journal of Psychiatric Practice 9:3, 195-208
CrossRef184
Cindy Parks Thomas, Stanley S Wallack, Sue Lee, Dennis McCarty, Robert Swift. (2003) Research to practice. Journal of Substance Abuse Treatment 24:1, 1-11
CrossRef185
(2003) Testing Combined Pharmacotherapies and Behavioral Interventions in Alcohol Dependence: Rationale and Methods. Alcoholism: Clinical & Experimental Research 27:7, 1107
CrossRef186
Richard J Bodnar, Maria M Hadjimarkou. (2002) Endogenous opiates and behavior: 2001. Peptides 23:12, 2307-2365
CrossRef187
JANET KAY BOBO. (2002) Tobacco Use, Problem Drinking, and Alcoholism. Clinical Obstetrics and Gynecology 45:4, 1169-1180
CrossRef188
Jose Guardia, Carlos Caso, Francisco Arias, Antoni Gual, Jordi Sanahuja, Marisa Ramirez, Ildefonso Mengual, Begona Gonzalvo, Lidia Segura, Joan Trujols, Miguel Casas. (2002) A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. Alcoholism: Clinical and Experimental Research 26:9, 1381-1387
CrossRef189
Mitchell H. Parks, Benoit M. Dawant, William R. Riddle, Steven L. Hartmann, Mary S. Dietrich, Mark K. Nickel, Ronald R. Price, Peter R. Martin. (2002) Longitudinal Brain Metabolic Characterization of Chronic Alcoholics With Proton Magnetic Resonance Spectroscopy. Alcoholism: Clinical and Experimental Research 26:9, 1368-1380
CrossRef190
A.Thomas McLellan. (2002) Technology transfer and the treatment of addiction: what can research offer practice?. Journal of Substance Abuse Treatment 22:4, 169-170
CrossRef191
Gad Lubin, Abraham Weizman, Mordechai Shmushkevitz, Avi Valevski. (2002) Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Human Psychopharmacology: Clinical and Experimental 17:4, 181-185
CrossRef192
Paul M Roman, J.Aaron Johnson. (2002) Adoption and implementation of new technologies in substance abuse treatment. Journal of Substance Abuse Treatment 22:4, 211-218
CrossRef193
(2002) Naltrexone for Alcohol Dependence. New England Journal of Medicine 346:17, 1329-1331
Full Text194
M Srisurapanont, N Jarusuraisin. 2002. Opioid antagonists for alcohol dependence. .
CrossRef195
Jos?? Guardia, Carlos Caso, Francisco Arias, Antoni Gual, Jordi Sanahuja, Marisa Ram??rez, Ildefonso Mengual, Bego??a Gonzalvo, Lidia Segura, Joan Trujols, Miguel Casas. (2002) A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. Alcoholism: Clinical & Experimental Research 26:9, 1381
CrossRef196
Mitchell H. Parks, Benoit M. Dawant, William R. Riddle, Steven L. Hartmann, Mary S. Dietrich, Mark K. Nickel, Ronald R. Price, Peter R. Martin. (2002) Longitudinal Brain Metabolic Characterization of Chronic Alcoholics With Proton Magnetic Resonance Spectroscopy. Alcoholism: Clinical & Experimental Research 26:9, 1368
CrossRef197
&NA;. (2002) Naltrexone proves disappointing in severe alcohol dependence. Inpharma Weekly &NA;:1319, 16
CrossRef198
Fuller, Richard K., Gordis, Enoch, . (2001) Naltrexone Treatment for Alcohol Dependence. New England Journal of Medicine 345:24, 1770-1771
Full Text
